Dr. David Zaccardelli is a biopharmaceutical executive with extensive leadership experience building and scaling life sciences companies. He served as President, Chief Executive Officer, and board member of Verona Pharma from 2020 until its $10 billion acquisition by Merck in 2025, leading the company through pivotal Phase 3 trials, FDA approval, and the launch of […]
Team Role: Board Of Directors
Jean-Paul Kress, MD
Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval and commercialization of Monjuvi® (tafasitamab), and advanced the company’s pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, strengthening MorphoSys’ position in oncology innovation […]
Wouter Joustra
Wouter Joustra is a General Partner at Forbion, where he is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion’s Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Prior to joining Forbion in 2019, Mr. Joustra was a Senior Trader and Executive Board member of the […]
Fouad Namouni, MD
Fouad Namouni, MD brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Dr. Namouni served as President, Research and Development of Blueprint Medicines Corporation, a global biopharmaceutical company, from September 2020 until its acquisition by Sanofi in 2025, where he helped build […]
Erez Kalir
Erez Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. He currently serves as the Managing Member of Martial Eagle Fund and as a Venture Partner at FJ Labs, renowned for its leadership in early-stage venture investments. He also authors the influential […]
Michel Detheux, PhD
Michel Detheux is the Chief Executive Officer of Muna Therapeutics. Prior to Muna, he served as Founder, President, and CEO of iTeos Therapeutics (NASDAQ: ITOS). He led the company from a research spin-off to a publicly traded clinical-stage entity, raising more than $1.2B and expanding to 180 employees across the US and Europe. Under his […]
Alexander (Bo) Cumbo
Mr. Cumbo has served as Solid’s President and Chief Executive Officer and as a director since December 2022. Mr. Cumbo served as the President and Chief Executive Officer and member of the Board of directors for AavantiBio from October 2020 until December 2022.From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility […]
Daniella Beckman
Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. From September 2019 to April 2026, she served as the Chief Financial Officer at Tango Therapeutics, where she oversaw finance, investor relations, and business development. Prior to joining Tango, she was […]